Prostate cancer (PCa), the most common male cancer, represents a real public health problem in terms of its frequency and severity in different countries around the world. It disproportionately affects people of African descent wherever they live in the world [1] .

Its incidence is generally characterized by a variability ranging from 1 to 30/100,000 inhabitants, depending on the geographical and/or ethnic characteristics of the populations.

This disparity implies the multiple interaction of environmental and genetic factors in its genesis. It is currently accepted that the African group as a whole is most at risk of developing (PCa).

According to GLOBOCAN 2022 estimates, prostate cancer is second only to bronchopulmonary cancer (14.2%) in the top 5 most common cancers in men [2] . And in both sexes, it ranks 4th after colorectal cancer, which ranks 3rd at 7.3%. The lowest incidences were recorded in Asian populations, and the highest in Northern Europe. Very high incidences are observed in Oceania and North America, mainly in the USA and Canada, where they are among the highest in the world [3] [4] .

In Africa, the overall incidence of (PCa) was 26.8 per 100,000 inhabitants. It varied considerably between the North and South of the Sahara (Table 1 see book). The incidence of this disease was 10.6 per 100,000 inhabitants in North Africa after lung cancer, and 27.9 per 100,000 inhabitants in Sub-Saharan Africa before liver cancer. In sub-Saharan Africa, incidences were 67.9 in the SAR, 34.7 in Guinea, 31.1 in the DRC, 37.4 in the Republic of Congo, 27.2 in Sierra Leone and 25.0 per 100,000 inhabitants in Angola [5] [6] .

Moreover, in the Democratic Republic of Congo, the absence of a national cancer registry is a serious handicap to the real epidemioclinical evaluation of prostate cancer (Figure 1, Figure 2 and Table 2).

Nevertheless, some studies have been carried out, among those of Kambere’s [7] on Epidemiological profile and histologic based outcome of prostatic cancer in Congolese patient following Gleason’s classification, Ngandu on PCa prevalence in Mbujimayi [8] , PCa risk factors [9] , PSA value in PCa diagnosis [10] , PCa histopronostic caracteristiques [11]

Source: GLOBOCAN 2012.

Frequency of prostate cancer on all analyzes in the pathological anatomy laboratory.

The figure shows that (PCa) accounts for 1.58% of all analyses carried out in the CUK Anapath laboratory (Figure 3).

PROSTATE CANCER FREQUENCY IN ALL CANCERS (Figure 4)

AGE OF SUBJECTS WITH PROSTATE CANCER

This Figure 5 shows that the 66-75 age group predominates, with 59% of all subjects.

HISTOLOGICAL TYPES

This table shows that Adenocarcinoma predominates with 87.8% (Table 2).

Type of sample

In our study, as shown in the table, biopsy dominated in 111 cases (84.1%) (Table 3 and Table 4).

DISTRIBUTION OF PATHOLOGIES OBSERVED IN THE PROSTATE

The table shows that non-cancerous lesions account for 51.3% of all pathologies observed.

DISTRIBUTION OF NON-CANCEROUS LESIONS IN THE PROSTATE

GLEASON SCORE (Figure 6)

63.8% of prostate cancers are high-risk (Table 5).

ISUP CLASSIFICATION

Of the 132 cases of prostate cancer diagnosed, 35 patients were classified as ISUP 1, i.e. 27%, 6 patients were classified as ISUP 2 (3 + 4), i.e. 5%, 7 patients were classified as ISUP 2 (4 + 3), i.e. 5%, 40 patients were classified as ISUP 4, i.e. 30%, and 44 patients were classified as ISUP 5, i.e. 33% (Figure 7).

This was a retrospective study. In our series, the frequency of prostate cancer represented 1.8% (Figure 3) of all laboratory analyses during the period of our study, in contrast to the study conducted by Halidou M et al. in Niger, which revealed 3.4% [6] .

This frequency differs from that of Kambere et al. who found a frequency of 0.12% [7] , and also from that of Lomba DIMONGO who noted a frequency of 0.3% [12] .

The somewhat reduced frequency may be explained by the population’s poor access to diagnosis due to a lack of adequate screening systems, but also by awareness of the seriousness of this pathology and the value of early diagnosis at a stage when the cancer is potentially curable.

Biopsy was the most common type of sampling in 111 of the 132 cases (See Table 3, i.e. 84.1% and Table 4). This result is justified by the fact that an increase in PSA above 4 nano-grams/milliliter is an absolute indication for prostate biopsy, especially if accompanied by information about cancer on digital rectal examination. Although in our series we have little clinical information on PSA levels, the little we do have indicates that the PSA level was above 4 nano-grams/milliliter (Figure 7).

In this study, prostate cancer accounted for 8% of all cancers in the pathological anatomy department of the University Clinics of Kinshasa, while the GLOBOCCAN 2022 revelations show that prostate cancer accounted for 7.3%, a result that is superimposed on the findings of the study by A. Ouatara et al. which revealed a frequency of 12% in Benin [13] .

Studies show that frequencies are disproportionately high in different regions.

The age group most affected is 66 - 75. This trend had been more or less the same in most studies. Many authors confirm that, worldwide, prostate cancer remains the cancer of the elderly.

The age group most affected is 66 - 75 (See Figure 5). This trend has been more or less the same in most studies. Many authors confirm that, worldwide, prostate cancer remains the cancer of the elderly, such as NGANDU TJ et al. who state that the majority were aware of the seriousness of the cancer, and 92% that it affected older men [10] .

Prostatic adenocarcinoma was the most common histological type, accounting for 92.4% (Table 2). This result is consistent with studies by various authors in most cases [11] .

In our series, 63.8% (Table 5) of prostate cancers were high-risk, a higher trend than in the study by Halidou M [6] .

In our series, histological findings according to ISUP group were as follows: ISUP 1 represented 27%, ISUP 2 10%, ISUP 4 30% and ISUP 5 33% of cases, a result which differs from that of Halidou M et al. [6] , whose ISUP 1 was 2.70%, ISUP 2 24.32%, ISUP 4 43.24% and ISUP 5 10.83%. This would be justified by the fact that in our study the number of cases is approximately double the number of cancers diagnosed in the Halidou M et al. series, i.e. 132 cases in our study and 74 cases for Halidou M et al.

Prostate cancer is a real public health problem. Worldwide, and in the Democratic Republic of Congo, it is the most frequently diagnosed cancer in men, and the leading cause of cancer-related death in men. In the DRC, because of the delay in consulting our patients and the weakness of systematic screening, patients are seen at an advanced stage of the disease. Treatment is multidisciplinary, involving surgery, radiotherapy and chemotherapy (including targeted therapies). Patient awareness and screening campaigns will help to considerably reduce the delay in diagnosis and the morbidity and mortality associated with prostate cancer. Given the high incidence of prostate cancer in African countries in general, and in the Democratic Republic of Congo in particular, it is important for decision-makers to implement a prostate cancer screening program, with good coverage of the population of men at risk throughout the country, Equip health facilities with screening equipment and Pathological Anatomy Laboratories to ensure adequate care for men with precancerous and cancerous prostate lesions in the DRC. Use audiovisual programs to raise awareness of the potential importance of prostate cancer screening. Pathologists: Intensify meetings between Urologists and Pathologists to reinforce and update prostate cancer screening strategies.

To researchers, initiate a prospective multicenter study to establish the immunohistochemical profile of prostate cancers, in association with genotyping, and initiate a study to search for genetic mutations in prostate cancers, enabling targeted therapy.

All authors declare that they have read and approved the final version of this manuscript.

We are grateful to the Oncology Department of Nganda Hospital for providing us with the information we needed to write this paper.

The authors declare no conflicts of interest regarding the publication of this paper.

Buanza, R.L., Lukuke, J.O., Lolangwa, F.B., Muela, A.M., Nkumu, M.L., Kabongo, F.B., Sitamuina, R.K. and Kabongo, J.-M.M. (2024) Epidemiological and Histopathological Profile of Prostate Cancer: A Retrospective Study in the Pathology Department of the University Clinics of Kinshasa. Journal of Cancer Therapy, 15, 239-249. https://doi.org/10.4236/jct.2024.156023